Literature DB >> 9015468

The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment.

P D Giles1, S Ramachandran, A J Whitaker, A W Phillips, S J Fell, A Mitchell, T D Coleman.   

Abstract

We describe a 'one-stop' cholesterol clinic implementing a regime based on the Scandinavian Simvastatin Survival Study (4S) in patients with established coronary heart disease in a district general hospital. The clinic has been established in collaboration with the cardiac rehabilitation centre. It was commissioned as an audit project by the purchasing authority, Walsall Health, a need having been shown in a previous audit. In the new clinic, audit is inbuilt, rather than being carried out as a separate retrospective exercise, and undertaken prospectively for all patients. Central to this is a database, used for routine correspondence and administration, as well as monitoring outcome. This application of information technology has improved clinical practice. Attendance at the clinic has been excellent. Half the consultations have resulted in therapeutic interventions, many of which may otherwise have been missed. Over 50% of patients were eligible for lipid-lowering medication under the protocol. Cholesterol targets based on 4S were achieved but with much lower drug doses, which may have major cost implications. Cholesterol levels measured within 24 hours of admission for myocardial infarction were poor predictors of results obtained after convalescence. After the clinic visit, most patients were taking aspirin plus one or two other secondary prevention treatments. Guidelines have been issued to primary care. Future plans for audit links with general practitioners, integration of the metabolic and cardiological assessment of survivors of myocardial infarction, and for long-term monitoring of clinical events in treated patients are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9015468      PMCID: PMC2398680          DOI: 10.1136/pgmj.72.854.744

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.

Authors:  K S Channer
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

2.  Increasing prescription of drugs for secondary prevention after myocardial infarction.

Authors:  J Smith; K S Channer
Journal:  BMJ       Date:  1995-10-07

3.  Lower patients' cholesterol now.

Authors:  M Oliver; P Poole-Wilson; J Shepherd; M J Tikkanen
Journal:  BMJ       Date:  1995-05-20

4.  Scandinavian simvastatin study (4S)

Authors:  G D Smith; J Pekkanen
Journal:  Lancet       Date:  1994 Dec 24-31       Impact factor: 79.321

5.  Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

Authors:  B Jönsson; M Johannesson; J Kjekshus; A G Olsson; T R Pedersen; H Wedel
Journal:  Eur Heart J       Date:  1996-07       Impact factor: 29.983

6.  How soon after myocardial infarction should plasma lipid values be assessed?

Authors:  R E Ryder; T M Hayes; I P Mulligan; J C Kingswood; S Williams; D R Owens
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

7.  Cholesterol reduction yields clinical benefit. A new look at old data.

Authors:  A L Gould; J E Rossouw; N C Santanello; J F Heyse; C D Furberg
Journal:  Circulation       Date:  1995-04-15       Impact factor: 29.690

8.  Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).

Authors:  U Goldbourt; S Behar; H Reicher-Reiss; J Agmon; E Kaplinsky; E Graff; Y Kishon; A Caspi; J Weisbort; L Mandelzweig
Journal:  Am J Cardiol       Date:  1993-04-15       Impact factor: 2.778

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

Authors:  A Keech; R Collins; S MacMahon; J Armitage; A Lawson; K Wallendszus; M Fatemian; E Kearney; V Lyon; J Mindell
Journal:  Eur Heart J       Date:  1994-02       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.